NASDAQ: SANASana Biotechnology Inc Stock
$1.75+0.04 (+2.34%)
Updated May 16, 2025
SANA Price
$1.75
Fair Value Price
$0.14
Market Cap
$393.59M
52 Week Low
$1.26
52 Week High
$9.02
P/E
-1.98x
P/B
1.88x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$208.67M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.13
Operating Cash Flow
-$206M
Beta
2.06
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SANA Overview
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SANA's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SANA
Ranked#289 of 456
Ranked#289 of 456
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $46.01 | A | |
| $8.19 | A | |
| $63.31 | A |
Be the first to know about important SANA news, forecast changes, insider trades & much more!
SANA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SANA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SANA ($1.75) is overvalued by 1,107.42% relative to our estimate of its Fair Value price of $0.14 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SANA ($1.75) is not significantly undervalued (1,107.42%) relative to our estimate of its Fair Value price of $0.14 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SANA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SANA due diligence checks available for Premium users.
Valuation
SANA fair value
Fair Value of SANA stock based on Discounted Cash Flow (DCF)
Price
$1.75
Fair Value
$0.14
Overvalued by
1,110.88%
SANA ($1.75) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SANA ($1.75) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SANA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SANA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.98x
Industry
-154.88x
Market
25.95x
SANA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.88x
Industry
4.21x
SANA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SANA's financial health
Profit margin
Revenue
$0.0
Net Income
-$49.4M
Profit Margin
0%
SANA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$445.5M
Liabilities
$236.4M
Debt to equity
1.13
SANA's short-term assets ($112.73M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SANA's long-term liabilities ($203.24M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SANA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$48.7M
Investing
$16.6M
Financing
$982.0k
SANA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SANA vs Biotech Stocks
Sana Biotechnology Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.